'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice

Simona Di Giambenedetto, Arturo Ciccullo, Chiara Picarelli, Damiano Farinacci, Arianna Emiliozzi, Alberto Borghetti, Gianmaria Baldin

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

It has been over a decade since the introduction of ralte-gravir, which has a well-established efficacy and tolera-bility profile . However, until recently, raltegravir hasonly been available as twice-daily formulations with, as aresult, a lower cumulative compliance to therapy and ahigher rate of discontinuation compared with the otheragents in the class .Following encouraging results from the ONCEMRK trial, a new raltegravir formulation of 1200 mg once dailywas introduced, and has been available in our centre sinceMay 2018. The new once-daily administration appearspromising in improving the compliance to raltegravir-con-taining regimens. However, during our routine clinicalactivity, we noticed that some of the patients recentlyswitched to raltegravir 1200 mg once daily were incor-rectly taking the drug. We then decided to investigate thisissue and to determine how widespread it was and pro-ceeded to recall all patients switched to this therapy in ourclinical centre between May 2018 and December 2018. Wethen asked our patients how they were taking raltegravirand collected their opinions on the ease of administrationof the new formulation and the onset of side effects.
Lingua originaleEnglish
pagine (da-a)1-2
Numero di pagine2
RivistaHIV Medicine
Volume21
DOI
Stato di pubblicazionePubblicato - 2020

Keywords

  • haart
  • therapy

Fingerprint Entra nei temi di ricerca di ''How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice'. Insieme formano una fingerprint unica.

Cita questo